Abs 0463 #ACR21 @RheumNow Park & colleagues compared treatment persistence across abatacept, TNFi, and JAKi in dual seropositive RA patients using Medicare database - Users of abatacept were more persistent to index time of 12 months and showed longer time to discontinuation https://t.co/0huE7zZjLq

#ClinicalPearl What lasts longer/⬆️retention in sero+ RA: Abatacept or TNFi or JAKi? #ACR21 abst#0463 @RheumNow Adjusting for confounding incl line of Rx / past bio Rx, #abatacept wins. But data not stratified for bio naive or exposed. Not sure if that would alter results https://t.co/1dEQncwPQF

We should aim for early treatment and good retention in ax-SpA to prevent structural evolution. >12 months of TNFi treatment in the previous 2 years associated w/ ⬇️ radiographic progression of SIJ in r- and nr-axSpA in GESPIC, #Abst0174 @RheumNow #ACR21 https://t.co/2V1q4dUwFO https://t.co/lxQU4zAP1I

• Tumor Necrosis Factor Inhibitors Show a Delayed Effect on Radiographic Sacroili…

Danish axSpA study shows pts in remission on TNFi may be able to taper and remain in remission at the 2 year mark. Abs0364 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/LBR5cSThQY https://t.co/sCqqhuBaTS

• Dose Tapering of TNF Inhibitors in Patients with Axial Spondyloarthritis in Rou…

Experts (Drs. M Clowse, Sammaratino) limit mAb TNFi 1 month b/f delivery or extend dosing. But, they do dose again for flares. Risk for infection is low based on the PIANO registry. Postpartum, they restart the meds w/in 1 week (vag delivery), 2 weeks C/S @rheumnow #pregnancy